Juha Yrjänheikki (CEO) and Laurent Décory (COO) will be attending the Swiss Biotech Day 2023 which will take place from 24-25 April in Basel, Switzerland. This will be a fantastic opportunity to meet investors and discuss potential partnerships with pharma companies.
The Swiss Biotech Day is one of the leading biotechnology conferences in Europe offering high-level experts from the life sciences industry. This event is ideal for networking, discussing, and discovering the latest trends in R&D, manufacturing, or innovative financing.
During this event, our CEO Juha Yrjänheikki will be presenting the Aurealis bacterial vector therapy platform, share insights into our latest Series A financing round, and resulting accelerated study plan in chronic wounds and Oncology.
Meet us there!
https://swissbiotechday.ch/
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.
For more information:
Aurealis Therapeutics:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com
